Literature DB >> 30954461

Establishment of an immunofluorescence assay to detect IgM antibodies to Nipah virus using HeLa cells expressing recombinant nucleoprotein.

Yoshihiro Kaku1, Eun-Sil Park2, Akira Noguchi2, Satoshi Inoue2, Ross Lunt3, Fedelino F Malbas4, Catalino Demetria4, Hui-Min Neoh5, Rahman Jamal5, Shigeru Morikawa2.   

Abstract

A novel indirect fluorescent antibody test (IFAT) for detection of IgM against Nipah virus (NiV) was developed using HeLa 229 cells expressing recombinant NiV nucleocapsid protein (NiV-N). The NiV IFAT was evaluated using three panels of sera: a) experimentally produced sera from NiV-N-immunized/pre-immunized macaques, b) post-infection human sera associated with a Nipah disease outbreak in the Philippines in 2014, and c) human sera from a non-exposed Malaysian population. Immunized macaque sera showed a characteristic granular staining pattern of the NiV-N expressed antigen in HeLa 229 cells, which was readily distinguished from negative-binding results of the pre-immunized macaque sera. The IgM antibody titers in sequential serum samples (n = 7) obtained from three Nipah patients correlated well with previously published results using conventional IgM capture ELISA and SNT serology. The 90 human serum samples from unexposed persons were unreactive by IFAT. The IFAT utilizing NiV-N-expressing HeLa 229 cells to detect IgM antibody in an early stage of NiV infection is an effective approach, which could be utilized readily in local laboratories to complement other capabilities in NiV-affected countries.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  IgM; Nipah virus; Serological assay

Mesh:

Substances:

Year:  2019        PMID: 30954461     DOI: 10.1016/j.jviromet.2019.03.009

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  1 in total

1.  Effective inactivation of Nipah virus in serum samples for safe processing in low-containment laboratories.

Authors:  Shumpei Watanabe; Shuetsu Fukushi; Toshihiko Harada; Masayuki Shimojima; Tomoki Yoshikawa; Takeshi Kurosu; Yoshihiro Kaku; Shigeru Morikawa; Masayuki Saijo
Journal:  Virol J       Date:  2020-10-09       Impact factor: 4.099

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.